The diabetic heart: metabolic causes for the development of a cardiomyopathy.
about
Influence of diabetes mellitus on heart failure risk and outcomeDecreased expression of beta1- and beta2-adrenoceptors in human diabetic atrial appendageFurther studies on antioxidant potential and protection of pancreatic beta-cells by Embelia ribes in experimental diabetesImpact of Type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heartReduced heart size and increased myocardial fuel substrate oxidation in ACC2 mutant miceInsulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway.Effects of type 1 diabetes mellitus on cardiac function: a study of monozygotic twins.Improvement of left ventricular diastolic dynamics in prediabetic stage of a type II diabetic rat model after troglitazone treatment.Cardiovascular actions of neurotrophinsOvernutrition and maternal obesity in sheep pregnancy alter the JNK-IRS-1 signaling cascades and cardiac function in the fetal heart.Cardiac-specific overexpression of HIF-1{alpha} prevents deterioration of glycolytic pathway and cardiac remodeling in streptozotocin-induced diabetic mice.Metabolic cardiomyopathies.Activation of the hexosamine biosynthesis pathway and protein O-GlcNAcylation modulate hypertrophic and cell signaling pathways in cardiomyocytes from diabetic miceThe cardioprotective role of beta-blockers in patients with diabetes mellitus.Acetyl-l-carnitine and oxfenicine on cardiac pumping mechanics in streptozotocin-induced diabetes in male Wistar ratsThe transcriptional coactivators, PGC-1α and β, cooperate to maintain cardiac mitochondrial function during the early stages of insulin resistanceFrequent non-cardiac comorbidities in patients with chronic heart failure.The PPARalpha-PGC-1alpha Axis Controls Cardiac Energy Metabolism in Healthy and Diseased Myocardium.α-Lipoic acid attenuates cardiac fibrosis in Otsuka Long-Evans Tokushima Fatty rats.Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism.Inhibition of p66ShcA redox activity in cardiac muscle cells attenuates hyperglycemia-induced oxidative stress and apoptosis.Impairment of insulin-stimulated Akt/GLUT4 signaling is associated with cardiac contractile dysfunction and aggravates I/R injury in STZ-diabetic rats.Role of differential signaling pathways and oxidative stress in diabetic cardiomyopathy.FoxO1 is crucial for sustaining cardiomyocyte metabolism and cell survival.Diabetic cardiomyopathy and its mechanisms: Role of oxidative stress and damage.Gene expression analysis in mitochondria from chagasic mice: alterations in specific metabolic pathways.Ketone bodies disturb fatty acid handling in isolated cardiomyocytes derived from control and diabetic ratsNutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart.Losartan reduces myocardial interstitial fibrosis in diabetic cardiomyopathy rats by inhibiting JAK/STAT signaling pathway.Calcium signaling-mediated endogenous protection of cell energetics in the acutely diabetic myocardium.Impaired diastolic function and elevated Nt-proBNP levels in type 1 diabetic patients without overt cardiovascular disease.Myocardial infarction and type II diabetes--preferential treatment for high risk patients?The metabolic "switch" AMPK regulates cardiac heparin-releasable lipoprotein lipase.Impact of altered substrate utilization on cardiac function in isolated hearts from Zucker diabetic fatty rats.Hormone-sensitive lipase knockout mice have increased hepatic insulin sensitivity and are protected from short-term diet-induced insulin resistance in skeletal muscle and heart.Activation of PPARgamma enhances myocardial glucose oxidation and improves contractile function in isolated working hearts of ZDF rats.PDC deletion: the way to a man's heart disease.PKC-{epsilon}-dependent survival signals in diabetic hearts.Overexpression of Gsalpha compensates for myocyte loss in diabetic cardiomyopathy.Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure.
P2860
Q24800363-637DB342-CCD8-4328-8909-495AC5D493B8Q24802547-1800C67E-AFC2-48F5-8ABD-E71AB0C8E842Q28218668-BEC738CF-8972-4BAD-9C40-F79E7E9652A6Q28276371-A76F55EE-E0D7-462B-A4A8-C61C4C909F54Q28584714-A873968D-F783-4321-8C89-9E647996D0B2Q30359509-EB771816-F1D9-415B-82C2-08D1F88D601AQ30535274-8C0C1B45-CD64-4B7C-B634-FDFDDF3B6F5DQ32016616-04FE6AA0-4256-4E10-AB74-C0371B95C088Q33719242-93BB7F94-F91C-481F-AFF1-894E33A156F7Q33868714-9D9C473C-3AA1-428E-9EE4-2774F3EDE564Q33947175-B238A325-FC53-4FE8-BD93-61519E1D6212Q34216280-D5FB8DD3-F1D0-4169-8656-F33C92C4FE2FQ34512181-1597B849-61A7-4207-97C7-E2A892BAEA70Q34782594-2859CBEE-20F4-48AD-83B2-916298A4EEC6Q34905231-1DA50E7E-0199-4FA1-88BF-D4BE756D3101Q35803717-D68265A1-3857-47D8-81D6-3E9F935507FEQ36046585-C22A3541-0878-4E81-9BF8-0435AF9BC726Q36426768-486F7654-891C-43D8-AD37-3A5DEC4AD34FQ36571926-F1DD46E0-8D24-42A0-B743-30FBE2337845Q36640675-B68EF4A6-4A92-46FE-AE7E-9502422C8404Q37100138-683BB8E4-7984-42FE-8C0D-37FC5EF1E2AAQ37339937-95C4F51B-402D-4C28-8A4A-17CE07A9412BQ37951439-6C509C99-128C-42E0-88AC-B08D007C4F63Q38069459-6850BA0E-C93A-4F46-B6F8-F47E8C41B017Q38271210-E29BCA76-6D87-4792-B5AB-AF2D0C9384B1Q40564183-E65ABA47-8330-44D8-9003-9B357AC113AAQ41817988-D599EE45-44E8-4B99-AD31-CA9540AEB3FEQ42593363-D2C795BE-E866-4292-9385-1754A9B7E99CQ43174462-07A6EF3C-BC68-4114-A5E5-0EF55D6C5861Q43211122-18117130-0BB3-416B-AA37-054AE62A65BAQ43859755-EA434B3F-6F73-46CC-83CF-4194F92493C9Q44181956-AB1D0BF0-4734-4F40-8316-2964C7CACC2BQ45029549-219AE4E5-4ED3-43AD-851D-D13CBCE13EC2Q45199020-A7CB693A-2262-493D-B2F4-45B967D2ECBEQ45258141-CCF6DB17-AF04-43CC-A8C0-A06598F8E5F8Q46410862-18C780BC-95D9-491E-85C7-C9BE2A3A0B4CQ46473218-B6D4E227-5B73-4C9D-A7EA-90831B5188F2Q46491162-DD765861-4559-44FC-AE0E-0448A6DBF23BQ46640265-6FCC5A2E-9594-431E-9150-897059FD83A4Q46817496-0E9CFD7D-1D3C-4FDB-9DD0-C688150E5D21
P2860
The diabetic heart: metabolic causes for the development of a cardiomyopathy.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
The diabetic heart: metabolic causes for the development of a cardiomyopathy.
@ast
The diabetic heart: metabolic causes for the development of a cardiomyopathy.
@en
type
label
The diabetic heart: metabolic causes for the development of a cardiomyopathy.
@ast
The diabetic heart: metabolic causes for the development of a cardiomyopathy.
@en
prefLabel
The diabetic heart: metabolic causes for the development of a cardiomyopathy.
@ast
The diabetic heart: metabolic causes for the development of a cardiomyopathy.
@en
P356
P1476
The diabetic heart: metabolic causes for the development of a cardiomyopathy.
@en
P2093
McNeill JH
Rodrigues B
P304
P356
10.1093/CVR/26.10.913
P577
1992-10-01T00:00:00Z